MCID: KLB004
MIFTS: 25

Klebsiella Infection

Categories: Rare diseases

Aliases & Classifications for Klebsiella Infection

MalaCards integrated aliases for Klebsiella Infection:

Name: Klebsiella Infection 53
Klebsiella Infections 73
Klebsiella 53

Classifications:



External Ids:

UMLS 73 C0022729

Summaries for Klebsiella Infection

NIH Rare Diseases : 53 Klebsiella infections refer to several different types of healthcare-associated infections that are all caused by the Klebsiella bacteria, including pneumonia; bloodstream infections; wound or surgical site infections; and meningitis. Healthy people usually do not get Klebsiella infections. However, people who are hospitalized and receiving treatment for other conditions may be susceptible to these infections. In healthcare settings, people who require long courses of antibiotics and/or devices such as ventilators (breathing machines) or intravenous (vein) catheters are at the most risk for Klebsiella infections. These infections are often treated with antibiotics, although some Klebsiella bacteria may be resistant to certain types of antibiotics.

MalaCards based summary : Klebsiella Infection, also known as klebsiella infections, is related to rhinoscleroma and craniosynostosis 1. An important gene associated with Klebsiella Infection is WDR26 (WD Repeat Domain 26). The drugs Colistin and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and kidney.

Related Diseases for Klebsiella Infection

Diseases related to Klebsiella Infection via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 rhinoscleroma 11.2
2 craniosynostosis 1 11.0
3 granuloma inguinale 11.0
4 pneumonia 11.0
5 immunodeficiency 30 10.9
6 endophthalmitis 10.2
7 spondyloarthropathy 1 9.8
8 spondylitis 9.8
9 thalassemia 9.6
10 pulmonary tuberculosis 9.6

Graphical network of the top 20 diseases related to Klebsiella Infection:



Diseases related to Klebsiella Infection

Symptoms & Phenotypes for Klebsiella Infection

Drugs & Therapeutics for Klebsiella Infection

Drugs for Klebsiella Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colistin Approved Phase 4,Phase 3,Not Applicable 1264-72-8, 1066-17-7 5311054
2
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2 55-56-1 9552079 2713
3
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
4
Ceftriaxone Approved Phase 4,Not Applicable 73384-59-5 5479530 5361919
5
Meropenem Approved, Investigational Phase 4,Phase 3 119478-56-7 64778 441130
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
8
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
9
Cephalexin Approved, Investigational, Vet_approved Phase 4,Phase 2 15686-71-2 27447
10
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
13
Polyestradiol phosphate Approved Phase 4 28014-46-2
14
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
15 Chlorhexidine gluconate Phase 4,Phase 3,Phase 2
16 methicillin Phase 4
17 Gentamicins Phase 4,Not Applicable
18 Dermatologic Agents Phase 4,Phase 3,Phase 2
19 Disinfectants Phase 4,Phase 3,Phase 2
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
22 Polymyxins Phase 4,Phase 3,Not Applicable
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
24 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Not Applicable
25 Antitubercular Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
26 Fluoroquinolones Phase 4,Phase 2,Phase 3,Early Phase 1
27 Contraceptive Agents Phase 4
28 Contraceptives, Oral Phase 4
29 Contraceptives, Oral, Combined Phase 4
30 Thienamycins Phase 4,Phase 3
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
32 Norgestimate, ethinyl estradiol drug combination Phase 4
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
34 Vaccines Phase 4,Not Applicable
35 Penicillanic Acid Phase 4,Phase 3
36 Estradiol 17 beta-cypionate Phase 4
37 Estradiol 3-benzoate Phase 4
38 Piperacillin, tazobactam drug combination Phase 4,Phase 3
39 Liver Extracts Phase 4,Not Applicable
40 beta-Lactamase Inhibitors Phase 4,Phase 3
41 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
42 Antibodies Phase 4
43 Immunoglobulins Phase 4
44 Bromides Phase 4
45
Ertapenem Approved, Investigational Phase 2, Phase 3,Not Applicable 153832-46-3 150610
46
Ciprofloxacin Approved, Investigational Phase 3,Phase 2,Not Applicable,Early Phase 1 85721-33-1 2764
47
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
48
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
49
Ofloxacin Approved Phase 3 82419-36-1 4583
50
Tigecycline Approved Phase 3 220620-09-7 5282044

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 SDD for Eradicating CRKP Carriage Unknown status NCT01761487 Phase 4
2 Safety and Efficacy Study of High Dose Colistin Unknown status NCT02162966 Phase 4 High Dose Colistin;Standard Dose Colistin
3 Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess Completed NCT00895089 Phase 4 Moxifloxacin (Avelox);ceftriaxone
4 Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Recruiting NCT02787863 Phase 4 Polioxidonium
5 Preventing Recurrent Urinary Tract Infections With α-D-mannose Recruiting NCT03497598 Phase 4 Mannose;Lactose
6 RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp. Terminated NCT02176122 Phase 4 Meropenem;Piperacillin-tazobactam combination product
7 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
8 Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA) Terminated NCT01400308 Phase 4 Mupirocin + Chlorhexidin
9 Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli Unknown status NCT00300560 Phase 3 Colistin
10 Prevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn Unknown status NCT00136370 Phase 3 Chlorhexidine
11 Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms Completed NCT00079989 Phase 3 tigecycline
12 Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis Completed NCT03047954 Phase 3 Broncho-Vaxom;Placebo - Cap
13 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
14 Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
15 Efficacy Of Bacterial Lysate In Asthmatic Children Completed NCT02541331 Phase 3
16 Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli Recruiting NCT01597973 Phase 3 colistin and meropenem;colistin and placebo
17 Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens Recruiting NCT03159078 Phase 3 Polymyxin B
18 Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Active, not recruiting NCT02729116 Phase 2, Phase 3 Sitafloxacin;Ertapenem
19 A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia Terminated NCT01110421 Phase 3 Cefepime placebo;Cefepime;Doripenem;Doripenem placebo;Amoxicillin/clavulanate potassium
20 Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia Unknown status NCT00722410 Phase 1, Phase 2 Polyethylene glycol
21 Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers Unknown status NCT02307383 Phase 2 Lactitol;Lactobacillus
22 Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients Completed NCT00123123 Phase 2 chlorhexidine gluconate oral rinse (0.12%);placebo
23 Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis Completed NCT00930982 Phase 2 Ciprofloxacin (Cipro, BAYQ3939);Placebo
24 Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness Recruiting NCT02148796 Phase 2 Broncho-Vaxom
25 The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" Recruiting NCT01595529 Phase 2 Cefixime;Cephalexin;Trimethoprim/Sulfamethoxazole
26 Pentaglobin in CRE and PA Neutropenic Infections Not yet recruiting NCT03494959 Phase 2 Pentaglobin
27 Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents Completed NCT01033383 Phase 1
28 Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers Withdrawn NCT02897999 Phase 1
29 Bacterial Transmission Dynamics Study Unknown status NCT02401204
30 A Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates Unknown status NCT01245829 Not Applicable
31 SATURN 04 Nosocomial Acquisition Study Unknown status NCT01208519
32 Microbiology and Clinical Outcome of Pneumonia Unknown status NCT00873522
33 Experimental Phage Therapy of Bacterial Infections Unknown status NCT00945087 Not Applicable
34 Stool Transplantation to Reduce Antibiotic Resistance Transmission Unknown status NCT02461199
35 Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting Unknown status NCT02339077
36 Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards Unknown status NCT02456818
37 The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy Completed NCT01612182
38 A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC). Completed NCT01266499 Not Applicable Colistin (Polymyxin E) 100mg x 4/d;both medications;will not receive PO treatment;PO Garamycin 80mg x 4/d
39 Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections Completed NCT03094494
40 Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species Completed NCT00518661
41 Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features Completed NCT01139112
42 Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care Completed NCT00167986 vancomycin-resistant enterococci and ESBL
43 Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin Completed NCT02604849 Neomycin;Streptomycin;Gentamicins
44 Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae Completed NCT00753558 Not Applicable Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
45 Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Completed NCT00167999 piperacillin-tazobactam
46 Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms Completed NCT01324726
47 Community - Associated Extended-spectrum Beta-lactamases (ESBL) Completed NCT00363220
48 Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis Completed NCT01961206
49 Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria Completed NCT01041716
50 Risk Factors for Linezolid Resistance in Staphylococcus Aureus Completed NCT00519025

Search NIH Clinical Center for Klebsiella Infection

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Klebsiella Infection

Anatomical Context for Klebsiella Infection

MalaCards organs/tissues related to Klebsiella Infection:

41
Colon, Liver, Kidney, Neutrophil, Lung

Publications for Klebsiella Infection

Articles related to Klebsiella Infection:

(show all 21)
# Title Authors Year
1
Newborn with rash due to Klebsiella infection. ( 28012933 )
2016
2
Evaluation of virulent multidrug resistant Klebsiella infection status in a tertiary care hospital in Eastern India. ( 23785917 )
2012
3
Intrapulmonary administration of leukotriene B(4) augments neutrophil accumulation and responses in the lung to Klebsiella infection in CXCL1 knockout mice. ( 22379035 )
2012
4
CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. ( 20937845 )
2010
5
Both TRIF- and MyD88-dependent signaling contribute to host defense against pulmonary Klebsiella infection. ( 19846873 )
2009
6
Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. ( 19342674 )
2009
7
Decreased neutrophil response in a model of chronic intraperitoneal Klebsiella infection. ( 17635060 )
2007
8
CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. ( 15470059 )
2004
9
STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection. ( 15356157 )
2004
10
Klebsiella infection in patients with thalassemia. ( 12594637 )
2003
11
Nosocomial Klebsiella infection in neonates in a tertiary care hospital: protein profile by SDS-page and klebocin typing as epidemiological markers. ( 17642987 )
2003
12
Exogenous cytokine modulation or neutralization of interleukin-10 enhance survival in lipopolysaccharide-hyporesponsive C3H/HeJ mice with Klebsiella infection. ( 10469238 )
1999
13
Hyperammonaemia due to Klebsiella infection in a neuropathic bladder. ( 9811390 )
1998
14
Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. ( 9125558 )
1997
15
Severe Klebsiella infection as a cause of mortality in neonates in Harare, Zimbabwe: evidence from postmortem blood cultures. ( 8284121 )
1993
16
Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. ( 8135915 )
1993
17
The relationship between Klebsiella infection and ankylosing spondylitis. ( 2670258 )
1989
18
Serum immunoglobulin levels in patients with active pulmonary tuberculosis and patients with Klebsiella infection. ( 3623633 )
1987
19
Klebsiella infection in a neonatal intensive care unit. ( 6397862 )
1984
20
Klebsiella infection in a neonatal intensive care unit: role of bacteriological surveillance. ( 6085092 )
1984
21
Klebsiella-induced LIF response in Klebsiella infection and ankylosing spondylitis. ( 6360292 )
1983

Variations for Klebsiella Infection

Expression for Klebsiella Infection

Search GEO for disease gene expression data for Klebsiella Infection.

Pathways for Klebsiella Infection

GO Terms for Klebsiella Infection

Sources for Klebsiella Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....